Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1535 of 5804
-
Drug-Free pain relief for sickle cell disease shows promise
Symptom relief CompletedThe investigators will conduct a hybrid type 1 effectiveness implementation trial to assess the effectiveness of acupuncture and guided relaxation on 360 people with Sickle Cell Disease (SCD), while observing and gathering information on implementation in three health systems: Un…
Phase: PHASE2 • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
New drug M701 aims to stop Cancer-Related fluid buildup without drains
Symptom relief CompletedA Phase II, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of M701 in treating Patients with Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer combined with Systemic Therapy.
Phase: PHASE2 • Sponsor: Wuhan YZY Biopharma Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could your own stem cells ease MS symptoms? new trial tests idea
Disease control CompletedRandomized Double-Blind Efficacy and safety study of Autologous HB-adMSCs versus placebo for the treatment of Multiple Sclerosis. This study will be for 24 subjects with 6 infusions over a 52 week period. Study participants will continue their established concomitant medications …
Phase: PHASE2 • Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for rare blood cancers: international trial tests smart drug cocktails
Disease control Recruiting nowABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (M…
Phase: PHASE1, PHASE2 • Sponsor: Michael Savona • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could ketamine lift the fog of depression in Parkinson's?
Symptom relief CompletedThe main purpose of this study is to examine the efficacy and safety of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD. A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether c…
Phase: PHASE2 • Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
Could less dialysis be better for seniors? new study aims to find out
Disease control Recruiting nowAs Korea is becoming a super-aged society, the number of elderly patients with end-stage kidney disease (ESKD) is expected to increase rapidly. Therefore, the burden on Korean society will also increase. Thrice-weekly hemodialysis is standard for renal replacement therapy. Howev…
Phase: NA • Sponsor: Soonchunhyang University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Virtual walking could ease nerve pain in spinal cord injury patients
Symptom relief Recruiting nowThe purpose of this study is to determine if playing a virtual reality walking game can help improve neuropathic pain in adults with chronic spinal cord injury.
Phase: NA • Sponsor: Texas A&M University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Real-World study tests upadacitinib for back pain in axial spondyloarthritis
Disease control OngoingAxial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain that might be difficult to distinguish from other causes of chronic back pain. Many particip…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug HPG1860 shows promise in reducing liver fat in NASH patients
Disease control CompletedThis is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.
Phase: PHASE2 • Sponsor: Hepagene (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Can turmeric and grape compounds help slow ALS?
Disease control CompletedAmyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders. Pathogenically, it is characterised by loss of oxidative control, excitotoxicity due to excess glutamate and i…
Phase: PHASE2 • Sponsor: Fundación Universidad Católica de Valencia San Vicente Mártir • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could a blood injection boost shoulder surgery success?
Disease control CompletedPurpose of the study: The aim of the study is to determine whether the postoperative administration of biological therapy with autologous platelet-rich plasma improves the clinical, imaging, and biochemical outcomes following surgical repair of a shoulder rotator cuff tear. Wha…
Phase: PHASE2 • Sponsor: KAT General Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Immune cells from tumors could fight advanced breast cancer
Disease control Recruiting nowThis study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy (GC 101 TIL) in patients with advanced breast cancer. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion tre…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden breast cancer cells
Diagnosis Recruiting nowThe purpose of this study is to find out whether pre-operative mpMRI using additional MRI sequences may improve surgical outcomes by providing more accurate information about the extent and acidity of the tumor than standard MRI, and to see whether the use of the fluorescent imag…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New inhaled antifungal shows promise for lung transplant patients
Disease control CompletedA study to evaluate the safety and tolerability of opelconazole for the prevention of fungal aspergillus infections in the lung in participants who have received a lung transplant.
Phase: PHASE2 • Sponsor: Pulmocide Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Huntington's drug shows promise for speech and gait issues
Symptom relief OngoingExamine the effects of deutetrabenazine on functional speech and gait impairment
Phase: PHASE2, PHASE3 • Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
AI boosts polyp detection in colonoscopy: over 5,000 tested
Knowledge-focused CompletedThe aim of this study is to investigate if the use of artificial intelligence (AI) in colonoscopy improves the polyp detection rate, and if the use of AI has a learning effect.
Phase: NA • Sponsor: Haraldsplass Deaconess Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
New drug CLN-049 aims to fight Hard-to-Treat blood cancers
Disease control Recruiting nowCLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pelvic implant aims to ease pain and restore mobility in fragile patients
Symptom relief Recruiting nowThe aim of this project is to assess the effectiveness of the IlluminOss pelvic implants in patients with pelvic metastatic disease presenting with pain, risk of pathologic fracture, non-displaced or minimally displaced pathologic fracture of the pelvis, and geriatric patients wi…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug TORL-1-23 enters first human tests
Disease control Recruiting nowThis first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for FSGS? obinutuzumab trial targets tough cases
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC